Call for Abstracts - 3rd International Conference on HIV Treatment Adherence

March 17-18, 2008
Hyatt Regency Hotel, Jersey City, NJ
Adherence to medical treatment for HIV/AIDS is an essential determinant of treatment success or failure. Yet, we still have much to learn about measurement, determinants, and interventions for HIV treatment adherence — these are complex challenges that require multidisciplinary cooperation among providers, researchers, government agencies, and patients.

The goal of this conference is to provide an international forum for the presentation and discussion of state-of-the-science HIV treatment adherence research, as well as current behavioral and clinical perspectives in practicum. Our ultimate hope is that this dialogue translates into evidence-based implementation of approaches for real world clinical and community settings.

Objectives
After attending this conference, participants will be able to:

  • Identify successes and challenges in HIV treatment adherence in various settings and populations worldwide
  • Understand behavioral and clinical aspects of adherence that reflect a variety of HIV treatment team perspectives (e.g., patients, physicians, pharmacists, nurses, mental health professionals, adherence specialists)
  • Describe the relationships between adherence, pharmacokinetics, viral suppression, and resistance
  • Understand the implications of adherence for HIV prevention and public health
  • Identify adherence assessment tools and interventions that can be integrated into patient care, including in resource-limited settings

Abstract Submissions
All abstracts will be submitted online, a direct link can be found at www.iapac.org. All submitted abstracts will be considered for oral and poster presentations. Late-breaker abstracts will be considered for poster presentations only. All submitted abstracts should report information not previously published, or intended to be published, prior to March 17, 2008.

Oral abstract and poster presenters at the conference must pay their own travel and accommodation expenses, as well as the applicable registration fees. A discounted registration rate is available until November 30, 2007.

It is the responsibility of the presenting author to ensure accuracy of content, spelling, and presentation. Abstracts will be published as submitted, subject to reformatting that may be required by the Conference Organizers.

For further information, please visit:
http://www.iapac.org

About IAPAC
IAPAC (International Association of Physicians in AIDS Care) is recognized under the law of the United States of America as a 501(c)(3) not-for-profit organization. Working in partnership with the healthcare professions, business government, academe, and religious communities, IAPAC accomplishes its mission through a comprehensive program of education, policy and advocacy, direct technical assistance, and care provision initiatives spearheaded by physician members.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...